Mizuho analyst Ann Hynes views the 9% post-earnings selloff yesterday in shares of HCA Healthcare as an overreaction. Expectations were high for a beat and a meaningful guidance raise going into the Q2 report given the significant outperformance in Q1, and HCA did not meet those expectations, Hynes tells investors in a research note. The analyst, however, does not believe there is any fundamental change to HCA's business. She keeps a Buy rating on the shares with a $153 price target.

Catheter Precision (VTAK) has received its first purchase order for LockeT from an HCA Healthcare (HCA) facility.

Augmedix (AUGX) announced the general availability of Augmedix Go for emergency departments, marking the launch of the industry's first fully-automated, generative AI powered medical documentation product for EDs across the country. The launch incorporates learnings from a pilot program with HCA Healthcare (HCA), one of the nation's leading healthcare providers. As part of the pilot, ED physicians in four HCA Healthcare hospitals utilized Augmedix Go to automate medical documentation, with the product instantaneously drafting their medical notes from patient visits. "The launch of Augmedix Go in the ED represents our unwavering commitment to develop solutions for health systems that improve their workflows. Our agility and flexible architecture, exhibited by our broad product suite and open network platform, help us address the complex and varying needs of clinicians and providers," said Manny Krakaris, CEO of Augmedix. "We have built a sophisticated platform designed to enable clinicians to be present with their patients while trusting that Augmedix technology is doing administrative work unobtrusively in the background."